<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369521</url>
  </required_header>
  <id_info>
    <org_study_id>22300</org_study_id>
    <nct_id>NCT04369521</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effects of a Low Free Sugar Diet in Patients With Nonalcoholic Fatty Liver Disease</brief_title>
  <official_title>Evaluation of the Effects of a Low Free Sugar Diet on Lipid Profile, Glycemic Indices, Liver Enzymes, Inflammatory Factors and Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Nutrition and Food Technology Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Nutrition and Food Technology Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effects of a low free sugar diet on lipid profile, glycemic indices, liver
      enzymes, inflammatory factors and hepatic steatosis and fibrosis in patients with
      Nonalcoholic fatty liver disease, 50 patients who referred to Gastrointestinal (GI) clinic
      with steatosis grade 2 and 3 will be randomly allocated to receive low free sugar diet or
      regular diet for 12 weeks; both groups will be advised to adherence the investigators'
      nutrition recommendation and exercise program too. At the first and the end of the
      intervention, lipid profiles, liver enzymes,glycemic indices, some inflammatory markers, and
      liver fibrosis will be assessed and compared between groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2019</start_date>
  <completion_date type="Anticipated">July 21, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 9, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALT</measure>
    <time_frame>12 weeks</time_frame>
    <description>serum level of Alanine transaminase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AST</measure>
    <time_frame>12 weeks</time_frame>
    <description>serum level of Aspartate transaminase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GGT</measure>
    <time_frame>12 weeks</time_frame>
    <description>serum level of Gamma glutaminase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TG</measure>
    <time_frame>12 weeks</time_frame>
    <description>serum level of Triglyceride</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>serum level of total cholesterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL-c</measure>
    <time_frame>12 weeks</time_frame>
    <description>serum level of LDL-Cholesterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL-c</measure>
    <time_frame>12 weeks</time_frame>
    <description>serum level of HDL-Cholesterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FBS</measure>
    <time_frame>12 weeks</time_frame>
    <description>serum level of Fasting blood sugar</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin</measure>
    <time_frame>12 weeks</time_frame>
    <description>serum level of Insulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hs-CRP</measure>
    <time_frame>12 weeks</time_frame>
    <description>Serum level of high-sensitive C-reactive protein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TNF-a</measure>
    <time_frame>12 weeks</time_frame>
    <description>Serum level of Tumor necrosis factor-a</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NF-kb</measure>
    <time_frame>12 weeks</time_frame>
    <description>Activity of Nuclear factor-B in peripheral monocellular cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver fibrosis</measure>
    <time_frame>12 weeks</time_frame>
    <description>Liver fibrosis according to fibroscan exam</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low free sugar diet with nutrition and exercise recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>regular diet with nutrition and exercise recommendation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>low free sugar diet</intervention_name>
    <description>low free sugar diet with nutrition and exercise recommendation</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age of 18 to 60 years

          2. Body Mass Index (BMI) between 25-40

          3. Sonographic findings compatible with hepatic steatosis (degree 2 or more)

        Exclusion Criteria:

          1. Alcohol consumption

          2. pregnancy or lactation

          3. Other liver disease (viral,cirrhosis,...)

          4. Use of drugs such as phenytoin,tamoxifen,lithium

          5. A history of Cancer, autoimmune disease,Renal disease &amp; Celiac disease, hypothyroidism
             or Cushing's syndrome

          6. Lack of desire to continue studying

          7. Have to use antibiotics with hepatotoxic drugs while studying

          8. Non-compliance with diet
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Azita Hekmatdoost, MD,PhD</last_name>
    <phone>+989123065084</phone>
    <email>a_hekmat2000@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azita Hekmatdoost</name>
      <address>
        <city>Tehran</city>
        <state>Middle East</state>
        <zip>19835</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azita Hekmatdoost, MD, PhD</last_name>
      <phone>+989123065084</phone>
      <email>a_hekmat2000@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Nutrition and Food Technology Research Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azita Hekmatdoost, MD, Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Nutrition and Food Technology Institute</investigator_affiliation>
    <investigator_full_name>Dr Azita Hekmatdoost</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

